Zanamivir has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


zanamivir studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
NAI40012 IV An Open-Label, Multi-center Study of the Patient Instructional Leaflet for RELENZA DISKHALER.
NAI30008 III A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study To Investigate The Efficacy And Safety Of Inhaled Zanamivir 10mg Administered Twice Daily For Five Days In The Treatment Of Influenza In Patients 12 Years Or Over Diagnosed With Asthma Or Chronic Obstructive Pulmonary Disease
NAI30009 III A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered by inhalation twice daily for five days in the treatment of symptomatic influenza A and B viral infections in children ages 5-12.
NAI30010 III A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered once a day for 10 days in the prevention of transmission of symptomatic influenza A and B viral infections within families.
NAI30012 III A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged = 65 Years.
NAI30015 III A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir 10mg administered twice daily for five days in the treatment of symptomatic influenza A and B viral infections in armed services personnel.
NAI30020 III A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled Zanamivir (10 mg bd. via Diskhaler), for 5 days, in high risk patients with symptomatic Influenza A and / or B infection.
NAI30028 III A double-blind, randomised, placebo-controlled, multicenter study in 2 parallel groups, to investigate the efficacy and safety of inhaled zanamivir (10 mg bd via Diskhaler), for 5 days, in children aged 5 to 12 years with symptomatic Influenza A and / or B infection.
NAI30031 III A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day for 10 Days in the Prevention of Transmission of Symptomatic Influenza A and B Viral Infections within Households
NAI30034 III A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicentre Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10 mg Administered Once a Day for 28 Days in the Prevention of Symptomatic Influenza A and B Viral Infections in Community-Dwelling High-risk Subjects aged >12 years
NAIA3002 III A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10 mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.
NAIA3003 III A Double-Blind, Randomized, Parallel-Group, Multi-Center Study to Investigate the Efficacy and Safety of Inhaled Zanamivir 10mg Administered Once a Day Compared to the Standard of Care in Controlling Nursing Home Influenza Outbreaks
NAIA3004 III A double-blind, randomized, placebo-controlled, parallel-group, multi-center study to investigate the efficacy and safety of inhaled zanamivir 10 mg once a day in controlling nursing home influenza outbreaks.
NAIA3005 III A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir (GG167) 10 mg administered once a day for 28 days in the prevention of symptomatic influenza A and B viral infections in community dwelling adults.
NAIB3001 III A double-blind, randomized, placebo-controlled, parallel-group, multicenter study to investigate the efficacy and safety of zanamivir administered twice daily in the treatment of influenza A and B viral infections in adults.
NAIB3002 III A double-blind, randomised, placebo-controlled, parallel-group, multicentre study to investigate the efficacy and safety of inhaled zanamivir (GG167) 10mg administered twice a day for five days in the treatment of symptomatic influenza A and B viral infections in adolescents and adults.
C94-085 (NAIB1002) I A Study to Evaluate the Effect of Repeat Doses of GG167 Dry Powder on Pulmonary Function and Bronchial Hyper-Responsiveness in Asthmatic Subjects
NAI106784 I Phase I, Open-label Study To Evaluate Steady-State Serum and Pulmonary Pharmacokinetics following Intravenous Administration of Zanamivir in Healthy Adult Subjects
NAI107485 I An Open Label, Single-Dose, Five-Way Crossover Study Examining Relative Oral Bioavailabilty of Zanamivir With Bioenhancing Excipients Following Direct Release Into Mid-Small Intestine Using Gamma Scintigraphy and the InteliSite Companion Capsule in Healthy Subjects.
NAI10901 I A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate the Effect of Inhaled Zanamivir 10mg od for 28 Days on Anti-Haemagglutinin Antibody Production (HAI Titre) Following Co-administration with Fluvirin™ Trivalent Influenza Vaccine in Healthy Adult Subjects
NAI10902 I An open label, randomized evaluation of the direct measurement of zanamivir concentrations in respiratory secretions following a single dose inhalation of 10mg RELENZA™ via DISKHALERÒ in health volunteers
NAIA1009 I Pharmacokinetics of zanamivir (GG167) following inhaled administration in pediatric subjects with signs and symptoms of respiratory illness.
Protocols C94-051 and C95-014; Study Report No. GCP/95/045 I A study to investigate the pharmacokinetics of GG167 in subjects with impaired renal function.